Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising pill may halt vitiligo and bring back pigment

NCT ID NCT06327321

Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests deucravacitinib, a daily pill that targets the immune system, to see if it can stop vitiligo from spreading and help skin regain its color. About 128 adults with non-segmental vitiligo will take the drug or a placebo for 24 weeks, then some will also receive UVB light therapy. The main goal is to measure at least a 50% improvement in facial depigmentation using a special camera.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deucravacitinib
What this could lead to
If successful, this could offer a new oral treatment to stop vitiligo from spreading and help restore skin color.
What could go wrong
This is a mid-stage trial with only 128 participants, so results may not apply to everyone. Deucravacitinib also carries risks like infection or side effects seen in similar drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women with non-segmental vitiligo. 2. ≥ 18 and \<75 years 3. Patient with at least one lesion of more than 2 cm² not located on the face, hands or feet. 4. Patients with Vitil-IA score above 5% and T-VASI above 5% (not taking into account the involvement of hands and feet) 5. For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed. 6. Affiliation to a social security system 7. Signed informed consent 8. Patient willing and able to attend all study visits Exclusion Criteria: 1. Pregnant or breast-feeding women. Or women with potential childbearing and not taking contraceptives or who plan to get pregnant during the study duration. 2. Segmental or mixed vitiligo 3. Concomitant use of topical or systemic immunosuppressive medication or steroids 4. Patients suffering from photodermatosis or taking photosensitive drugs 5. Personal history of skin cancer 6. Personal history of cancer of less than 5 years 7. Patients with active infection 8. Tuberculosis or latent tuberculosis 9. Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship or deprived of freedom 10. Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo, generalized are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized vitiligo vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo, generalized

Contacts and locations

Locations

  • APHP, Henri Mondor

    Paris, Creteil, France

  • CHU de Bordeaux

    Bordeaux, Talence, 33000, France

  • CHU de Lille

    Lille, France

  • CHU de Nice - Hôpital de l'Archet

    Nice, Alpes-Maritimes, 06200, France

  • HCL

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.